indication

Acute Schizophrenia

Competitive landscape

as of 2026-07-01
Competitive set
7
6 approved · 1 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
55 events
2020
2024
2028
2032
2036
2040
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugRecruiting
Brexpiprazole (Rexulti)
US-approved 2015 · Rexulti
Phase 34 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2033
drugNot Yet Recruiting
Aripiprazole
US-approved 2002 · ABILIFY
Phase 32 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugUnknown
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 41 trial
OwnerAstraZeneca
Protection—
drugUnknown
Haloperidol
US-approved 1986 · Haldol Decanoate
Phase 41 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 31 trial
OwnerEli Lilly and Company
Protection2041
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
Phase 31 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Brilaroxazine
Pipeline · Phase 2
Phase 21 trial
OwnerReviva Pharmaceuticals
Protection—

Market size

prevalence as a range, not a number